Intuitive Surgical (NASDAQ:ISRG) Cut to “Hold” at Erste Group Bank

Intuitive Surgical (NASDAQ:ISRG) was downgraded by stock analysts at Erste Group Bank from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

ISRG has been the topic of a number of other research reports. Leerink Partners lifted their price target on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Barclays raised their price objective on Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. Stifel Nicolaus raised their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Raymond James raised their price objective on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Finally, UBS Group raised their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $611.86.

Intuitive Surgical Trading Down 1.0 %

Shares of ISRG opened at $483.95 on Monday. The business’s 50-day moving average price is $565.43 and its 200 day moving average price is $531.90. The stock has a market capitalization of $172.37 billion, a P/E ratio of 75.50, a P/E/G ratio of 5.85 and a beta of 1.43. Intuitive Surgical has a 1-year low of $364.17 and a 1-year high of $616.00.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Robert Desantis sold 11,545 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the sale, the executive vice president now directly owns 5,224 shares in the company, valued at $2,607,925.28. The trade was a 68.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Fredrik Widman sold 810 shares of Intuitive Surgical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $573.78, for a total value of $464,761.80. Following the completion of the transaction, the vice president now directly owns 473 shares of the company’s stock, valued at $271,397.94. This represents a 63.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,754 shares of company stock worth $17,691,621 over the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors have recently modified their holdings of the business. Atala Financial Inc acquired a new position in Intuitive Surgical in the 4th quarter worth about $25,000. Hurley Capital LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $28,000. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter valued at about $26,000. Parvin Asset Management LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $26,000. Finally, BankPlus Trust Department bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.